Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul-Aug;76(4):229-239.
doi: 10.1016/j.ihj.2024.07.005. Epub 2024 Jul 14.

The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review

Babu Ezhumalai  1 , Ranjan Modi  2 , Manokar Panchanatham  3 , Dhamodaran Kaliyamoorthy  4
Affiliations
Review

The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review

Babu Ezhumalai et al. Indian Heart J. 2024 Jul-Aug.

Abstract

Novel therapies for heart failure with reduced ejection fraction (HFrEF) are angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose co-transporter 2 inhibitor (SGLT2i), etc. The purpose of this review is to determine the effects of ARNI and SGLT2i in heart failure (HF), compare the impact of SGLT2i with ARNI, and finally evaluate the current data regarding the combination of these two drugs in HF. Various trials on the respective medications have shown some significant reduction in all-cause mortality and cardiovascular (CV) death. The combination of these drugs has shown more CV benefits than monotherapy. There is emerging data about these two drugs in patients with heart failure with preserved ejection fraction (HFpEF). At present, there are less head-to-head comparison trials of these two drugs. This review provides insights on the current evidence, comparative efficacy, and combination therapy of ARNI and SGLT2i in managing HF, focussing on HFrEF and HFpEF.

Keywords: ARNI; Angiotensin receptor neprilysin inhibitor; Heart failure; SGLT2i; Sodium-glucose Co-Transporter 2 inhibitor.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Rahamim E., Nachman D., Yagel O., et al. Contemporary pillars of heart failure with reduced ejection fraction medical therapy. J Clin Med. 2021;10(19):4409. - PMC - PubMed
    1. Dargad R.R., Prajapati M.R., Dargad R.R., Parekh J.D. Sacubitril/valsartan: a novel angiotensin receptor-neprilysin inhibitor. Indian Heart J. 2018;70(1):S102–S110. Suppl 1. - PMC - PubMed
    1. Ponikowski P., Voors A.A., Anker S.D., et al. Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. - PubMed
    1. Kaplinsky E. Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Ther Adv Chronic Dis. 2016;7(6):278–290. - PMC - PubMed
    1. Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Card Fail. 2017;23(8):628–651. - PubMed

MeSH terms

Substances